Cargando…
LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies
BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and i...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666888/ https://www.ncbi.nlm.nih.gov/pubmed/23702046 http://dx.doi.org/10.1186/1471-2350-14-55 |
_version_ | 1782271401793683456 |
---|---|
author | Saj, Michal Bilinska, Zofia T Tarnowska, Agnieszka Sioma, Agnieszka Bolongo, Pierrette Sobieszczanska-Malek, Malgorzata Michalak, Ewa Golen, Dorota Mazurkiewicz, Lukasz Malek, Lukasz Walczak, Ewa Fidzianska, Anna Grzybowski, Jacek Przybylski, Andrzej Zielinski, Tomasz Korewicki, Jerzy Tesson, Frederique Ploski, Rafal |
author_facet | Saj, Michal Bilinska, Zofia T Tarnowska, Agnieszka Sioma, Agnieszka Bolongo, Pierrette Sobieszczanska-Malek, Malgorzata Michalak, Ewa Golen, Dorota Mazurkiewicz, Lukasz Malek, Lukasz Walczak, Ewa Fidzianska, Anna Grzybowski, Jacek Przybylski, Andrzej Zielinski, Tomasz Korewicki, Jerzy Tesson, Frederique Ploski, Rafal |
author_sort | Saj, Michal |
collection | PubMed |
description | BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro. METHODS: Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening. RESULTS: We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia, although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation, fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model. CONCLUSIONS: In conclusion, in the two referral centre populations, the screening revealed five mutations among 66 heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44 consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members. |
format | Online Article Text |
id | pubmed-3666888 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36668882013-05-30 LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies Saj, Michal Bilinska, Zofia T Tarnowska, Agnieszka Sioma, Agnieszka Bolongo, Pierrette Sobieszczanska-Malek, Malgorzata Michalak, Ewa Golen, Dorota Mazurkiewicz, Lukasz Malek, Lukasz Walczak, Ewa Fidzianska, Anna Grzybowski, Jacek Przybylski, Andrzej Zielinski, Tomasz Korewicki, Jerzy Tesson, Frederique Ploski, Rafal BMC Med Genet Research Article BACKGROUND: LMNA mutations are most frequently involved in the pathogenesis of dilated cardiomyopathy with conduction disease. The goal of this study was to identify LMNA mutations, estimate their frequency among Polish dilated cardiomyopathy patients and characterize their effect both in vivo and in vitro. METHODS: Between January, 2008 and June, 2012 two patient populations were screened for the presence of LMNA mutations by direct sequencing: 66 dilated cardiomyopathy patients including 27 heart transplant recipients and 39 dilated cardiomyopathy patients with heart failure referred for heart transplantation evaluation, and 44 consecutive dilated cardiomyopathy patients, referred for a family evaluation and mutation screening. RESULTS: We detected nine non-synonymous mutations including three novel mutations: p.Ser431*, p.Val256Gly and p.Gly400Argfs*11 deletion. There were 25 carriers altogether in nine families. The carriers were mostly characterized by dilated cardiomyopathy and heart failure with conduction system disease and/or complex ventricular arrhythmia, although five were asymptomatic. Among the LMNA mutation carriers, six underwent heart transplantation, fourteen ICD implantation and eight had pacemaker. In addition, we obtained ultrastructural images of cardiomyocytes from the patient carrying p.Thr510Tyrfs*42. Furthermore, because the novel p.Val256Gly mutation was found in a sporadic case, we verified its pathogenicity by expressing the mutation in a cellular model. CONCLUSIONS: In conclusion, in the two referral centre populations, the screening revealed five mutations among 66 heart transplant recipients or patients referred for heart transplantation (7.6%) and four mutations among 44 consecutive dilated cardiomyopathy patients referred for familial evaluation (9.1%). Dilated cardiomyopathy patients with LMNA mutations have poor prognosis, however considerable clinical variability is present among family members. BioMed Central 2013-05-23 /pmc/articles/PMC3666888/ /pubmed/23702046 http://dx.doi.org/10.1186/1471-2350-14-55 Text en Copyright © 2013 Saj et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Saj, Michal Bilinska, Zofia T Tarnowska, Agnieszka Sioma, Agnieszka Bolongo, Pierrette Sobieszczanska-Malek, Malgorzata Michalak, Ewa Golen, Dorota Mazurkiewicz, Lukasz Malek, Lukasz Walczak, Ewa Fidzianska, Anna Grzybowski, Jacek Przybylski, Andrzej Zielinski, Tomasz Korewicki, Jerzy Tesson, Frederique Ploski, Rafal LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
title | LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
title_full | LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
title_fullStr | LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
title_full_unstemmed | LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
title_short | LMNA mutations in Polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
title_sort | lmna mutations in polish patients with dilated cardiomyopathy: prevalence, clinical characteristics, and in vitro studies |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3666888/ https://www.ncbi.nlm.nih.gov/pubmed/23702046 http://dx.doi.org/10.1186/1471-2350-14-55 |
work_keys_str_mv | AT sajmichal lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT bilinskazofiat lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT tarnowskaagnieszka lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT siomaagnieszka lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT bolongopierrette lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT sobieszczanskamalekmalgorzata lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT michalakewa lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT golendorota lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT mazurkiewiczlukasz lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT maleklukasz lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT walczakewa lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT fidzianskaanna lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT grzybowskijacek lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT przybylskiandrzej lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT zielinskitomasz lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT korewickijerzy lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT tessonfrederique lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies AT ploskirafal lmnamutationsinpolishpatientswithdilatedcardiomyopathyprevalenceclinicalcharacteristicsandinvitrostudies |